Incretin combination therapy for the treatment of non-alcoholic steatohepatitis - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Diabetes, Obesity and Metabolism Année : 2020

Incretin combination therapy for the treatment of non-alcoholic steatohepatitis

Aimo Kannt
Andreas Nygaard Madsen
  • Fonction : Auteur
Claire Kammermeier
  • Fonction : Auteur
Ralf Elvert
  • Fonction : Auteur
Tim Klöckener
  • Fonction : Auteur
Martin Bossart
  • Fonction : Auteur
Torsten Haack
  • Fonction : Auteur
Andreas Evers
  • Fonction : Auteur
Katrin Lorenz
  • Fonction : Auteur
W. Hennerici
  • Fonction : Auteur
Corinne Rocher
  • Fonction : Auteur
Zsolt Böcskei
  • Fonction : Auteur
Vincent Mikol
  • Fonction : Auteur
Michael Wagner
  • Fonction : Auteur

Résumé

Aims: Agonists to the glucagon-like peptide 1 receptor (GLP1R) agonists and dual agonists targeting GLP1R and the glucagon receptor (GCGR) or the Glucose-dependent insulinotropic peptide receptor (GIPR) are currently being developed for the treatment of non-alcoholic steatohepatitis (NASH). We have tested specific mono-agonists to these three receptors individually and in combination in a mouse model of diet-induced NASH and fibrosis, to decipher the contribution of their activities and potential additive effects on improving systemic and hepatic metabolism. Materials and methods: Advanced NASH was induced by pre-feeding C57BL/6J mice a diet rich in fat, sucrose and cholesterol for 36 weeks. This was followed by eight weeks of treatment with the receptor-specific agonists 1-GCG (20 µg/kg bid sc), 2-GLP1 (3 µg/kg bid sc) or 3-GIP (30 µg/kg bid sc), or the dual (1+2) or triple (1+2+3) combinations thereof. A dual GLP1R/GCGR agonistic peptide, 4-dual-GLP1/GCGR (30 µg/kg bid sc), and liraglutide (100 µg/kg bid sc) were included as references. Results: Whereas 1-GCG and 3-GIP alone, at the selected low dose, did not influence body weight, liver lipids and histology, their combination with 2-GLP1 provided additional weight loss, reduction in liver triglycerides and improvement in histological NAFLD activity score (NAS). In addition, there was a trend to further reduction in markers of hepatic inflammation and fibrosis. Notably, compared to high-dose liraglutide, 4-dual-GLP1R/GCG as well as the dual and triple combinations of selective mono-agonists demonstrated stronger improvement in NAS at the same extent of body weight loss. Conclusions: GCGR and GIPR agonism provide additional, body weight-independent improvement in a murine model of advanced NASH with fibrosis on top of GLP1R agonism.
Fichier principal
Vignette du fichier
KANNT Diab Ob Metab.pdf (1.58 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

inserm-02777445 , version 1 (04-06-2020)

Identifiants

Citer

Aimo Kannt, Andreas Nygaard Madsen, Claire Kammermeier, Ralf Elvert, Tim Klöckener, et al.. Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. Diabetes, Obesity and Metabolism, 2020, Online ahead of print. ⟨10.1111/dom.14035⟩. ⟨inserm-02777445⟩
343 Consultations
403 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More